CTLA4 and hypothyroidism: Hypothyroidism and thyrotoxicosis, followed by hypothyroidism, were revealed in Lee and colleagues’ retrospective study that was conducted on patients treated with pembrolizumab or nivolumab monotherapy and in combination with anti-CTLA4, emphasizing the importance of monitoring thyroid function while being treated with these therapies [15].